1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)

@inproceedings{Neven20151850SO,
  title={1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)},
  author={Patrick Neven and Daniele Giulio Generali and E Ciruelos and Adijaya Yusuf and Joaqu{\'i}n Gavil{\'a} and Claudia Bighin and Marleen V. Borms and Pierfranco F. Conte and Filippo Montemurro and Donata Sartori and Teak V Lee and Maura Camozzi and Katia Lorizzo and Ozlem Ocak and Guy Jerusalem},
  year={2015}
}

Topics from this paper.

Similar Papers

Loading similar papers…